Effectiveness of second generation antipsychotics: A systematic review of randomized trials

Johnsen, Erik; Jørgensen, Hugo
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: Systematic reviews based on efficacy trials are inconclusive about which second generation antipsychotic drug (SGA) should be preferred in normal clinical practice, and studies with longer duration and more pragmatic designs are called for. Effectiveness studies, also known as naturalistic, pragmatic, practical or real life studies, adhere to these principles as they aim to mimic daily clinical practice and have longer follow-up. Objective: To review the head-to-head effectiveness of SGAs in the domains of global outcomes, symptoms of disease, and tolerability. Methods: Searches were made in Embase, PubMED, and the Cochrane central register of controlled trials for effectiveness studies published from 1980 to 2008, week 1. Different combinations of the keywords antipsychotic*, neuroleptic* AND open, pragmatic, practical, naturalistic, real life, effectiveness, side effect*, unwanted effect*, tolera* AND compar* AND random* were used. Results: Sixteen different reports of randomized head-to-head comparisons of SGA effectiveness were located. There were differences regarding sample sizes, inclusion criteria and follow-up periods, as well as sources of financial sponsorship. In acute-phase and first-episode patients no differences between the SGAs were disclosed regarding alleviating symptoms of disease. Olanzapine was associated with more weight gain and adverse effects on serum lipids. In the chronic phase patients olanzapine groups had longer time to discontinuation of treatment and better treatment adherence compared to other SGAs. The majority of studies found no differences between the SGAs in alleviating symptoms of psychosis in chronically ill patients. Olanzapine was associated with more metabolic adverse effects compared to the others SGAs. There were surprisingly few between-drug differences regarding side effects. First generation antipsychotics were associated with lower total mental health care costs in 2 of 3 studies on chronically ill patients, but were also associated with more extrapyramidal side effects compared to the SGAs in several studies. Conclusion: In chronically ill patients olanzapine may have an advantage over other SGAs regarding longer time to treatment discontinuation and better drug adherence, but the drug is also associated with more metabolic side effects. More effectiveness studies on first-episode psychosis are needed.


Related Articles

  • Olanzapine.  // Reactions Weekly;Dec2015, Vol. 1580 Issue 1, p276 

    The article describes the case of an 18-year-old male patient who developed oculogyric crisis (OGC) after being treated with olanzapine.

  • Antipsychotic drug warnings indicate need for better communication between endocrinologists, psychiatrists. Milone, Angelo // Endocrine Today;Jun2010 Supplement, Vol. 8, p1 

    The article emphasizes the need for endocrinologists and psychiatrists to communicate better in relation to the warning issued by the U.S. Food and Drug Administration (FDA) on the adverse metabolic effects of second-generation antipsychotic drug olanzapine in adolescents.

  • Olanzapine/topiramate.  // Reactions Weekly;5/4/2013, Issue 1451, p38 

    The article describes a case of hallucinations, renal tubular acidosis and restlessness that developed in a 13-year-old adolescent girl during treatment with topiramate and olanzapine for mental disorder and epilepsy.

  • Induction of manic symptoms by novel antipsychotics. Fahy, S.; Fahy, T. J. // British Journal of Psychiatry;Jun2000, Vol. 176, p597 

    A letter to the editor is presented which reports a case of 55-year-old woman with a 20-year history of chronic anxiety and recurrent depressive episodes who developed subjective excitement, increased psychomotor activity, insomnia, irritability and racing thoughts within three days of being...

  • Olanzapine.  // Reactions Weekly;2/27/2010, Issue 1290, p36 

    The article describes the case of two male patients who acquired tardive oculogyric crises (OGCs) while undergoing treatment with olanzapine.

  • Aripiprazole/olanzapine/quetiapine.  // Reactions Weekly;Dec2015, Vol. 1580 Issue 1, p47 

    The article describes the cases of several elderly patients who died or developed stroke after being treated with aripiprazole, olanzapine or quetiapine.

  • Olanzapine.  // Reactions Weekly;Dec2015, Vol. 1580 Issue 1, p275 

    The article describes the case of a 44-year-old male patient who developed acute pancreatitis after being treated for schizophrenia with olanzapine.

  • Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Guo, Xiaofeng; Fang, Maosheng; Zhai, Jinguo; Wang, Bo; Wang, Chuanyue; Hu, Bin; Sun, Xueli; Lv, Luxian; Lu, Zheng; Ma, Cui; Guo, Tiansheng; Xie, Shiping; Twamley, Elizabeth; Jin, Hua; Zhao, Jingping // Psychopharmacology;Aug2011, Vol. 216 Issue 4, p475 

    Rationale: The relative effectiveness of the atypical antipsychotic drugs and conventional agents in patients with early-stage schizophrenia has not been comprehensively determined. Objectives: The aim of our study was to evaluate the efficacy and safety of seven antipsychotic drugs for the...

  • Does Olanzapine Warrant Clinical Pharmacokineti Monitoring in Schizophrenia? Schwenger, Erin; Dumontet, Jane; Ensom, Mary H. H. // Clinical Pharmacokinetics;2011, Vol. 50 Issue 7, p415 

    Olanzapine, a second-generation antipsychotic, is a first-line agent in the treatment of schizophrenia. The objective of this review was to determine whether olanzapine warrants clinical pharmacokinetic monitoring in patients with schizophrenia, using a previously published decision-making...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics